IXHL revenueFY2026$0
- FY YoY
- -100.0%
IXHL revenue was $0 for fiscal 2026 (ended Jun 30, 2026), down 100.0% from fiscal 2025.
Incannex Healthcare Inc. (IXHL) financials
For fiscal 2026 (ended Jun 30, 2026), Incannex Healthcare Inc. reported $0 of revenue and -$19.30M of net income.
- Revenue, FY2026
- $0
- Revenue growth, YoY
- -100.0%
- Net income, FY2026
- -$19.30M
- Free cash flow, FY2026
- -$12.88M
- EPS, diluted, FY2026
- -$1.66
- Cash
- $67.71M
- Market cap
- $27.5M
FY2020FY2026
FY2020FY2026
FY2023FY2026
IXHL revenue and earnings growth
IXHL net incomeQ4 2026-$2.49M
IXHL net income was -$2.49M in fiscal Q4 2026 (ended Jun 30, 2026), compared with -$31.60M a year earlier. For the full fiscal 2026 it was -$19.30M, compared with -$46.88M in fiscal 2025.
IXHL EPSQ4 2026-$0.11
IXHL diluted EPS was -$0.11 in fiscal Q4 2026 (ended Jun 30, 2026). For the full fiscal 2026 it was -$1.66.
IXHL free cash flowQ4 2026$3.37M
IXHL free cash flow was $3.37M in fiscal Q4 2026 (ended Jun 30, 2026), compared with -$1.48M a year earlier. For the full fiscal 2026 it was -$12.88M, compared with -$12.52M in fiscal 2025.
Income statement
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $86.0K | $12.0K | $362.8K | $6.3K | $1.90M | $604.9K |
| Cost of revenue | - | - | - | - | $6.3K | $912.0K | $450.3K |
| Gross profit | - | - | - | - | -$67 | $985.6K | $154.5K |
| Research and development | $5.21M | $10.75M | $12.88M | $6.31M | $5.37M | $4.75M | $2.11M |
| Selling, general and admin | $17.82M | $13.13M | $17.17M | $8.01M | $281.0K | $99.1K | $457.7K |
| Operating income | -$23.03M | -$23.79M | -$30.04M | -$49.67M | - | - | - |
| Interest expense | $0 | $303.0K | - | - | - | - | - |
| Pre-tax income | -$19.30M | -$46.88M | -$18.43M | -$48.81M | -$14.90M | -$11.37M | -$3.93M |
| Income tax | $0 | $0 | $30.0K | - | - | - | - |
| Net income | -$19.30M | -$46.88M | -$18.46M | -$48.81M | -$14.90M | -$11.37M | -$4.70M |
| EPS, basic | -$1.66 | -$40.82 | -$34.50 | -$99.60 | -$37.50 | -$34.80 | -$20.70 |
| EPS, diluted | -$1.66 | -$40.82 | -$34.50 | -$99.60 | -$37.50 | -$34.80 | -$17.10 |
| Diluted shares | 11.7M | 1.1M | 538,811.267 | 512,823.467 | 39.7M | - | - |
Balance sheet
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $67.71M | $15.04M | $5.86M | $22.12M | $25.83M | $9.12M | $3.60M |
| Receivables | - | - | - | $287.5K | $294.7K | $169.1K | $413.3K |
| Current assets | $72.83M | $19.96M | $16.20M | $23.00M | $37.88M | $9.33M | $4.24M |
| Total assets | $72.98M | $20.45M | $17.05M | $23.78M | $37.88M | $9.33M | $4.24M |
| Current liabilities | $1.49M | $6.98M | $5.62M | $2.55M | $2.01M | $755.0K | $1.07M |
| Total liabilities | $5.61M | $7.06M | $5.83M | $2.96M | $2.01M | $755.0K | $1.07M |
| Shareholders' equity | $67.37M | $13.39M | $11.22M | $20.82M | $24.71M | $8.57M | $3.16M |
Cash flow
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$12.87M | -$12.51M | -$15.85M | -$10.75M | -$12.81M | -$6.91M | -$3.91M |
| Capital expenditures | $10.0K | $8.0K | $277.0K | $316.0K | - | - | - |
| Free cash flow | -$12.88M | -$12.52M | -$16.12M | -$11.06M | - | - | - |
| Investing cash flow | -$94.0K | -$8.0K | -$277.0K | -$316.0K | - | $29.3K | $13.0K |
| Financing cash flow | $65.90M | $21.40M | - | $8.18M | $41.18M | $12.40M | $7.40M |
| Share repurchases | $9.40M | $0 | - | - | - | - | - |
| Stock-based compensation | $7.56M | $2.61M | $8.93M | $2.15M | $1.46M | $600.0K | $565.4K |
| Depreciation and amortization | $240.0K | $246.0K | $103.0K | $88.0K | - | - | - |
Key ratios
| Line item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 |
|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | -100.0% | 616.7% | -96.7% | 5684.8% | -99.7% | 213.7% | - |
| Gross margin | - | - | - | - | -1.1% | 51.9% | 25.5% |
| Operating margin | - | -27661.6% | -250341.7% | -13691.5% | - | - | - |
| Net margin | - | -54517.4% | -153825.0% | -13455.2% | -237664.0% | -599.3% | -776.6% |
| Free cash flow margin | - | -14559.3% | -134350.0% | -3050.2% | - | - | - |
| Return on equity | -28.6% | -350.2% | -164.6% | -234.4% | -60.3% | -132.6% | -148.5% |
| Return on assets | -26.4% | -229.3% | -108.3% | -205.2% | -39.3% | -121.9% | -110.9% |
| Current ratio | 48.81 | 2.86 | 2.88 | 9.02 | 18.84 | 12.36 | 3.95 |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | $0 | $0 | $12.0K | $74.0K | - | - | - | - |
| Research and development | $1.49M | $321.0K | $2.28M | $1.12M | $3.70M | $2.73M | $1.41M | $2.90M | $4.36M | $3.28M | $2.64M | $2.61M |
| Selling, general and admin | $3.70M | $3.73M | $4.71M | $5.67M | $3.83M | $2.27M | $3.60M | $3.43M | $5.40M | $4.14M | $5.34M | $2.28M |
| Operating income | -$5.19M | -$4.05M | -$7.00M | -$6.79M | -$7.53M | -$5.00M | -$5.00M | -$6.25M | -$9.74M | -$7.42M | -$7.98M | -$4.89M |
| Interest expense | - | - | -$5.0K | -$5.0K | $0 | $132.0K | -$28.0K | -$28.0K | - | - | - | - |
| Pre-tax income | -$2.49M | -$3.88M | -$6.52M | -$6.41M | -$31.60M | -$3.97M | -$5.89M | -$5.42M | -$6.43M | -$6.03M | -$5.24M | -$726.0K |
| Net income | -$2.49M | -$3.88M | -$6.52M | -$6.41M | -$31.60M | -$3.97M | -$5.89M | -$5.42M | -$6.46M | -$6.03M | -$5.24M | -$726.0K |
| EPS, basic | -$0.11 | -$0.35 | -$0.60 | -$0.60 | - | -$6.19 | -$9.90 | -$8.70 | -$10.80 | -$11.40 | -$9.90 | -$2.40 |
| EPS, diluted | -$0.11 | -$0.35 | -$0.60 | -$0.60 | - | -$6.19 | -$9.90 | -$8.70 | -$10.80 | -$11.40 | -$9.90 | -$2.40 |
| Diluted shares | - | 12.3M | 11.6M | 10.3M | - | 654,418 | 587,480.733 | 588,094.4 | - | 529,103.767 | 529,103.767 | 529,103.767 |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $67.71M | $74.45M | $68.90M | $73.28M | $15.04M | $6.71M | $2.10M | $3.63M | $5.86M | $9.34M | $14.55M | $16.28M |
| Current assets | $72.83M | $80.09M | $74.68M | $78.30M | $19.96M | $15.63M | $10.50M | $15.21M | $16.20M | $16.32M | $21.33M | - |
| Total assets | $72.98M | $80.28M | $75.01M | $78.72M | $20.45M | $16.20M | $11.11M | $16.05M | $17.05M | $17.25M | $22.36M | - |
| Current liabilities | $1.49M | $1.93M | $1.55M | $1.65M | $6.98M | $7.37M | $5.84M | $9.23M | $5.62M | $2.86M | $3.19M | - |
| Short-term debt | - | - | - | - | - | $1.40M | $1.38M | - | - | - | - | - |
| Long-term debt | - | - | - | - | - | - | $2.38M | - | - | - | - | - |
| Total debt | - | - | - | - | - | - | $3.77M | - | - | - | - | - |
| Total liabilities | $5.61M | $5.05M | $1.60M | $1.71M | $7.06M | $8.79M | $10.14M | $9.45M | $5.83M | $3.11M | $3.49M | - |
| Shareholders' equity | $67.37M | $75.23M | $73.41M | $77.01M | $13.39M | $7.40M | $964.0K | $6.59M | $11.22M | $14.14M | $18.87M | $19.79M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $3.37M | -$2.46M | -$4.62M | -$9.16M | -$1.48M | -$3.16M | -$5.63M | -$2.25M | -$3.64M | -$4.35M | -$2.10M | -$5.75M |
| Capital expenditures | -$1.0K | $5.0K | $4.0K | $2.0K | $0 | $0 | - | - | $3.0K | -$6.0K | $59.0K | $221.0K |
| Free cash flow | $3.37M | -$2.46M | -$4.63M | -$9.16M | -$1.48M | -$3.16M | - | - | -$3.65M | -$4.36M | -$2.16M | -$5.97M |
| Investing cash flow | -$30.0K | -$18.0K | -$4.0K | -$42.0K | $0 | $0 | - | - | -$3.0K | $6.0K | -$59.0K | -$221.0K |
| Financing cash flow | -$6.91M | $4.71M | $927.0K | $67.18M | $9.60M | $7.74M | $4.10M | -$52.0K | - | - | - | - |
| Share repurchases | $7.08M | $1.14M | - | - | - | - | - | - | - | - | - | - |
| Stock-based compensation | $1.19M | $1.47M | $2.28M | $2.63M | $1.30M | $417.0K | $435.0K | $459.0K | $3.34M | $2.11M | $3.27M | $201.0K |
| Depreciation and amortization | $50.0K | $65.0K | $59.0K | $66.0K | $61.0K | -$5.0K | $126.0K | $64.0K | $62.0K | $17.0K | $12.0K | $12.0K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating margin | - | - | - | - | - | - | -41700.0% | -8451.4% | - | - | - | - |
| Net margin | - | - | - | - | - | - | -49116.7% | -7324.3% | - | - | - | - |
| Current ratio | 48.81 | 41.56 | 48.27 | 47.51 | 2.86 | 2.12 | 1.80 | 1.65 | 2.88 | 5.70 | 6.70 | - |
| Debt to equity | - | - | - | - | - | - | 3.91 | - | - | - | - | - |
Source: XBRL data Incannex Healthcare Inc. files with the SEC, latest filing dated Sep 25, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-30, first reported May 15, 2026.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
IXHL peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| IXHL | $0 | -100.0% | -$19.30M | - | $27.5M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
IXHL FAQ
8 questionsWhat is IXHL revenue?
Incannex Healthcare Inc. (IXHL) reported $0 of revenue for fiscal 2026 (ended Jun 30, 2026). That is down 100.0% from the year before.Is IXHL profitable?
No. Incannex Healthcare Inc. reported a net loss of $19.30M for fiscal 2026 (ended Jun 30, 2026).How much cash and debt does IXHL have?
Incannex Healthcare Inc. reported $67.71M in cash and cash equivalents on its most recent balance sheet in SEC filings.How fast is IXHL revenue growing?
Incannex Healthcare Inc.'s revenue changed -100.0% in fiscal 2026, to $0.What is IXHL free cash flow?
Incannex Healthcare Inc. generated -$12.88M of free cash flow for fiscal 2026 (ended Jun 30, 2026), which is operating cash flow of -$12.87M less capital expenditures.What is IXHL earnings per share?
Diluted earnings per share were -$1.66 for fiscal 2026 (ended Jun 30, 2026), from SEC filings, restated for any stock split those filings show.When did IXHL last report financial results?
The latest statements here come from Incannex Healthcare Inc.'s 10-K filed on Sep 25, 2026, covering the period ended Jun 30, 2026.Where does this IXHL financial data come from?
Quantisnow builds these statements from the structured XBRL data Incannex Healthcare Inc. files with the SEC. It is provided for information only and is not investment advice.